Leveraging practice-based research networks to accelerate implementation and diffusion of chronic kidney disease guidelines in primary care practices: a prospective cohort study

Table 4 CKD performance outcome measures for wave I and wave II practices

Performance measure	Wave I			Wave II
Performance measure	Pre-intervention period	Post-intervention period	pvalue*	Pre-intervention period	Post-intervention period	pvalue*
If eGFR <60	N = 374			N = 660
ACE or ARB prescribed: n (%)	232 (63%)	255 (69%)	0.002	354 (55%)	407 (63%)	<0.001
Taking NSAIDs: n (%)	25 (7%)	18 (5%)	0.10	51 (8%)	45 (7%)	0.44
A1c testing performed: n (%)	288 (77%)	297 (79%)	0.25	492 (89%)	487 (88%)	0.65
Urine microalbumin test performed: n (%)	158 (42%)	175 (47%)	0.16	NA	NA	NA
LDL test performed: n (%)	309 (83%)	305 (82%)	0.75	NA	NA	NA
A1c test results: Mean (SD)	7.1% (1.4)	7.2% (1.5)	0.78	7.4% (1.6)	7.3% (1.5)	0.07
Systolic BP measure (mmHg): mean (SD)	132.5 (16.3)	132.8 (16.0)	0.72	132.0 (15.9)	131.4 (14.9)	0.39
Diastolic BP measure (mmHg): mean (SD)	72.8 (9.1)	72.7 (9.0)	0.93	72.0 (9.4)	71.7 (8.5)	0.48
LDL test result (mg/dl): mean (SD)	89.8 (36.6)	90.2 (32.8)	0.84	96.3 (38.1)	92.0 (34.5)	0.004
If eGFR <45	N = 138			N = 233
Hemoglobin test performed: n (%)	84 (61%)	100 (72%)	0.02	NA	NA	NA
Vitamin D testing (or supplement): n (%)	51 (37%)	83 (60%)	<0.001	87 (37%)	132 (57%)	<0.001

SD standard deviation, NA not applicable because it was an annual recommendation and in wave II, the post-intervention period was only 9 months.
*McNemar’s test was used to generate p values for categorical-scaled outcomes and the paired t test for continuous-scaled outcome measures.

ISSN: 1748-5908